Key result
The global switch from trivalent to bivalent oral poliovirus vaccine highlighted that low population immunity is a critical risk factor for the emergence of circulating vaccine-derived poliovirus.
This editorial highlights the challenges of the polio endgame, emphasizing the risks of circulating vaccine-derived poliovirus and the critical role of population immunity during the global transition away from oral poliovirus vaccines.
Ending Use of Oral Poliovirus Vaccine The global health community has taken the first step toward eliminating use of oral poliovirus vaccine: switching from trivalent to bivalent vaccine. The polio endgame requires monitoring the effects on circulating viruses, followed by other challenging steps.
No takes yet. Share an insight, caveat, or question.
Mark A. Pallansch (2018) conducted an editorial in Poliovirus infection. Oral Poliovirus Vaccine (OPV) cessation was evaluated. The global switch from trivalent to bivalent oral poliovirus vaccine highlighted that low population immunity is a critical risk factor for the emergence of circulating vaccine-derived poliovirus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: